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Germline mutations in the BRCA1 and BRCA2 genes are associated with significantly
increased risks for ovarian cancer. The National Comprehensive Cancer Network (NCCN)
currently recommends that female BRCA mutation carriers undergo risk-reducing salpingooophorectomy (RRSO) after age 35; however, not all women elect this option. The purpose of
this study was to prospectively survey women with BRCA mutations currently undergoing
ovarian cancer screening about their intention to have an RRSO and the various factors
influencing their decision. Of the 26 women who completed our survey, 26 (100%, CI: 86.8100) plan to undergo an RRSO in their lifetime. The average woman reported 6.7 motivations
and 2.9 barriers to RRSO, indicating that in our population women tend to have more reasons
for electing, rather than avoiding, this surgery. We further found that while most women
appeared to share the same motivations for surgery, they often had unique barriers that were not
common to others. The most important reasons in favor of surgery included a desire to reduce
one’s risk for ovarian cancer and live longer for family members. The most important barrier to
RRSO was fear of the symptoms related to menopause. We believe these results will assist
healthcare providers when discussing the option of RRSO with BRCA mutation carriers
undergoing ovarian cancer screening.
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INTRODUCTION
Hereditary breast and ovarian cancer (HBOC) syndrome due to germline mutations in
the BRCA1 or BRCA2 genes accounts for approximately 10% of all cases of ovarian cancer. The
average lifetime risk of ovarian cancer is up to 45% with a BRCA1 mutation and up to 25% with
a BRCA2 mutation, compared with a 1.7% lifetime risk for the general population [1]. These
risks are especially concerning given that the vast majority (>79%) of these malignancies are
detected at an advanced stage and the 5-year survival rate after diagnosis is only 45% (data from
SEER 18 2005-2011). The National Comprehensive Cancer Network (NCCN) currently
recommends that women with HBOC undergo risk-reducing salpingo-oophorectomy (RRSO)
prior to natural menopause to reduce the risk of ovarian cancer by 85-90% and also decrease
overall cancer-related mortality [2-4]. Despite the effectiveness of RRSO, uptake of surgery by
mutation carriers is not universal, with estimates suggesting that in the United States
approximately 25-35% of carriers do not elect surgery and remain at elevated risk [5, 6]. While
ovarian cancer screening options are available, including pelvic examination, serum CA-125
analysis, and transvaginal ultrasound, these procedures are not significantly effective at
detecting an early stage malignancy or reducing ovarian cancer related mortality [7].
A number of quantitative and qualitative research studies have investigated factors
associated with the uptake of RRSO by women with HBOC. The most commonly reported
sociodemographic variables include older age, particularly ≥40-years [8], and parity [8-10].
Researchers have also investigated the influence of personal and family history of cancer on
decision making, but findings have been inconsistent. Women with a personal history of breast
cancer may have a preference for RRSO over screening [11-13]; however, not all evidence
supports this [14, 15]. It is similarly unclear if family history of breast or ovarian cancer
significantly affects uptake of RRSO, with some quantitative studies suggesting an association
1

[8, 16], while others do not [17, 18]. One qualitative study noted that experiencing a family
member die from breast or ovarian cancer heavily influenced the uptake of risk reducing
surgeries, including RRSO [19].
Additional investigations have sought to determine the psychosocial factors that
influence decision making, particularly perceived cancer risk and cancer-related anxiety.
Numerous studies have concluded that women with HBOC have a higher perceived cancer risk
and this significantly impacts their decisions about RRSO [14-16, 20]. Similar evidence also
supports that women with high levels of cancer-related anxiety are more likely to opt for this
surgery [5, 21] as a means of alleviating these distressing feelings [22]. Interestingly, two large
studies have found no evidence of a relationship between anxiety and uptake of RRSO [9, 18],
so its true impact remains unclear. Personal values, such as wanting to gain more control over
one’s cancer risk, as well as a sense of obligation to stay healthy for other family members have
also been cited as important factors for women considering RRSO [18, 19]. Finally, limited
research has investigated how the concepts of body image, femininity and self-identity affect
decision-making; however, available studies suggest that these may be relevant barriers to
surgery [20, 23, 24].
An important consideration for women undergoing RRSO is the immediate onset of
early menopause with the potential for adverse sexual outcomes and increased risks for multiple
health problems. Compared to women who enter menopause naturally, women with surgicallyinduced menopause may have more severe vasomotor symptoms, as well as a higher frequency
of dyspareunia (pain during intercourse) and reduced sexual satisfaction [25]. Multiple studies
have also linked early-onset menopause to an increased risk for cardiovascular disease [26],
osteoporosis [27], and an overall increased risk of mortality [28]. Despite the well-documented
risks of early-menopause, the effects of this information on mutation carriers’ decisions have
2

not been well established. A handful of qualitative studies have reported that at-risk women
perceive the onset of menopausal symptoms as a major limitation of the surgery [10, 24, 29,
30], but additional research is needed to determine how these concerns compare to other factors
women consider when deciding about RRSO.
The purpose of this study was to prospectively survey women with BRCA mutations
currently undergoing ovarian cancer screening about their future intentions to elect or avoid
RRSO. Simultaneously, we also investigated the various factors that are influencing this
decision. The novelty of our design is that we had participants rank their influences, thereby
allowing us to elucidate the relative importance of each within a woman’s decision making
process. Our analysis included both a chart review for sociodemographic and clinical variables,
as well as a questionnaire that evaluated psychosocial factors, and other previously reported
influences, such as onset of menopause, femininity/identity, quality of life concerns, perception
of ovarian cancer screening, and family history. In doing so we hoped to better identify the most
important motivations and barriers to women who are considering this surgery in the context of
an ovarian cancer screening program.

METHODS
Study population
All participants were recruited from the University of Texas MD Anderson Cancer
Center, Gynecologic Oncology High-Risk Screening Clinic. Eligibility criteria included women
35-years or older with a confirmed pathogenic mutation in the BRCA1 or BRCA2 genes who
were undergoing ovarian cancer screening. Women had to have at least 1 ovary in situ. Potential
participants were excluded if they had a personal history of ovarian cancer, RRSO, or if they
were not fluent in both verbal and written English.
3

Data collection
Eligible women were approached by a research study member during their visit to the
high-risk Gynecologic Oncology screening clinic. Each woman was given a verbal overview of
the study and then asked about her desire to participate. If a woman expressed interest in the
study she was provided an informed consent document to review and sign, which was then
collected by the research study member. Each woman was also given a copy of the signed
consent document for her own records. Following informed consent, all sociodemographic, and
clinical data were obtained through a review of the electronic medical record. Each woman also
provided her preferred email and was subsequently sent a link to a confidential survey
administered through the REDCap (Research Electronic Data Capture) web-based survey
application. Approval for this study was obtained from the Institutional Review Board (IRB) of
The University of Texas MD Anderson Cancer Center.

Demographic and clinical information
A review of each woman’s medical record was performed to gather demographic and
clinical information. This included date of birth, ethnicity, race, religion, health insurance,
highest level of education achieved, marital status, employment, date of genetic testing results,
BRCA1 and BRCA2 mutation status, personal cancer history, menstrual status, gravidity, parity,
age at parity, history of contraception use, fertility treatment, hormone replacement therapy
(HRT), breast cancer screening, mastectomy history, Tamoxifen use, date of first gynecologic
screening at MD Anderson, total number of gynecologic screening visits at MD Anderson, and
outcomes of gynecologic screening, such as transvaginal ultrasound and CA-125 results.

4

Cancer risk perceptions
Three items were adapted from Gurmankin Levy et al. [31] to measure women’s
perceptions of their ovarian cancer risk. Women indicated their numerical risk for ovarian
cancer on a scale of 0% to 100% with 10 digit intervals. 0% corresponded to no risk for cancer
and 100% corresponded to a certainty of developing cancer. In addition, women were asked to
rate their risk for developing cancer on a Likert-type scale with answers including, very low,
moderately low, neither high nor low, moderately high, or very high. For the final question
women reported how their risk compares to the average woman’s risk with options including
much lower than, a little lower than, the same as, a little higher than, or much higher than the
average woman’s risk.

Cancer-specific worry
We assessed cancer worry using the Lerman cancer worry scale adapted for ovarian
cancer [32]. This consisted of 3 Likert-style questions measuring how often women think about
ovarian cancer, if these thoughts have affected their mood, and if these thoughts have interfered
with their daily activities. Scores can range from 3 to 12 with higher scores indicating a higher
level of worry.

Anxiety
The State-Trait Anxiety Inventory (STAI) Form Y was used to evaluate anxiety in our
population [33]. This tool includes 40 questions that measure either state (i.e. temporary), and
trait (i.e. inherent) anxiety. All questions are Likert-style with a 4 point scale, and higher scores
correspond to higher levels of anxiety.

5

Intent for RRSO
Women were asked to report if and when they plan to have an RRSO. Possible answer
choices included: age 35-40, age 41-45, age 46-50, after age 50, after menopause, or never.

Factors influencing decision making
To identify factors influencing decision making regarding RRSO women were given a
list of 17 factors that may be motivating their desire to have surgery and a separate list of 24
factors that may be discouraging them from having surgery. Women were allowed to select all
factors that were applicable to them, and there was an additional “other” option in which they
could record their own factor if it was not already provided. Factors provided in the survey were
based on a literature review of surgical decision-making and/or clinical experience of the
authors. After selecting relevant factors, women were asked to choose the 5 most important
factors for each category (motivating and discouraging) and rank these in an order of 1 to 5 with
1 being the most important for their decision making and 5 being the least important. If a
participant initially selected less than 5 factors she was asked to rank these from 1 through the
number she selected. She could also choose not to rank any of her selections. A weighted
scoring algorithm was used to compare the various factors based on women’s rankings. A rank
of 1 was given 5 points, 2 was 4 points, 3 was 3 points, 4 was 2 points and 5 was 1 point. The
total score for each factor was then used for comparisons.

Data analysis
Analysis of demographic and clinical information, as well as all survey variables consisted of
measures of central tendency and descriptive statistics. An exact binomial confidence interval
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Demographic

Number of
Participants

Percentage (%)

was used for the proportion of women who self-reported a desire to have an RRSO in their
lifetime.

RESULTS
Demographic characteristics
35 women were invited to participate in this study and all agreed to sign the informed
consent documents. 27 of the 35 women completed the online survey, giving us an initial
response rate of 77%. One participant’s results were excluded from analysis because she
completed the survey after having a RRSO so our final assessment consisted of 26 women (74%
of those consented). The demographic characteristics of these women are summarized in Table
1. The average age of our population was 43.9 years with a range of 35-66 years. The majority
of women (17, 65%) were white, married (21, 81%), had at least some college education (20,
77%) and were employed (19, 73%). All women surveyed had health insurance, with private
plans being the most common (21, 81%). Regarding mutation status, 12 (46%) women had a
BRCA1 mutation and 14 (54%) had a BRCA2 mutation. The average age at disclosure of genetic
testing results was 42.5 years with a range of 29-66 years, and 14 (56%) had their genetic
testing coordinated through MD Anderson. 15 women (57%) had a personal history of cancer,
all of which had breast cancer, and of those 15, 10 were actively undergoing treatment at the
time of survey completion.
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Age
Median (Range)
Mean
Race
African America
American Indian
Asian
White
Hispanic
Unknown
Education
High school
Some college/ associates degree
Bachelor’s or advanced degree
Unknown
Religion
Christian
Other
None or not reported
Marital Status
Married
Divorced
Single
Employment
Employed
Unemployed
Insurance
Private
Medicaid
Medicare
BRCA1 mutation
BRCA2 mutation
Age at BRCA results
Mean (Range)
Genetic testing through MD Anderson
Personal History of Cancer
Breast cancer
Currently undergoing cancer treatment

42 (35-66) years
43.9 years
4/26
1/26
3/26
17/26
5/26
1/26

15
4
12
65
19
4

4/26
7/26
13/26
2/26

15
27
50
8

15/26
5/26
6/26

58
19
23

21/26
1/26
4/26

81
4
15

19/26
7/26

73
27

21/26
4/26
1/26
12/26
14/26

81
15
4
46
54

42.5 (29-66) years
14/26
15/26
15/15
10/26

56
57
100
38

Table 1: Demographic characteristics of survey participants, (N = 26)
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Gynecologic and breast history
Information regarding women’s gynecologic and breast history is summarized in Table
2. A little over half (58%) of women were premenopausal and the majority (81%) were parous.
4 of the 26 women (15%) had a previous hysterectomy, 7 (27%) had a tubal ligation, and 13
(50%) used oral contraceptives with an average use of 9.5 years. For women who received their
genetic testing through MD Anderson, the average time between disclosure of BRCA results
and the first documented visit for high-risk gynecologic screening was 4 months, with a range
of 0-13 months. The majority of women, regardless of where they had their genetic testing, had
been followed for less than 1 year in the MD Anderson screening clinic at the time of survey
completion. More specifically, the mean length of follow up was 12.9 months and ranged from
0 to 82 months. Of the 26 women in our study, 1 (4%) had a previous abnormal CA-125
screening result at MD Anderson and no one had an abnormal transvaginal ultrasound.
Regarding breast history, 20 women (77%) were also followed in the MD Anderson Breast
Screening Clinic with the mean length of follow up being 29.1 months (range 0-218 months). 15
women (58%) had a previous mastectomy (bilateral or unilateral) and 3 (12%) used Tamoxifen.

Cancer risk perceptions
When women were asked to indicate their numerical lifetime risk in units of 10 (range 0100) all recorded at least a 10% risk with 22 women (85%) choosing a risk of 50% or higher.
The most commonly chosen risks were 50% or 60% with 6 women selecting each of these
categories. 5 additional women selected 70%, 2 selected 80%, 2 selected 90%, and 1 selected
100%. None of the women selected 30% or 40% as a risk number. Type of BRCA mutation did
not appear to influence numerical risk perception. When asked about their qualitative risk
perceptions, the majority of women (22, 85%) indicated that their lifetime risk for developing
9

ovarian cancer is “moderately high” or “very high”. 3 (11%) considered their risk to be “neither
high nor low”, and 1 woman (4%) categorized her risk as “moderately low”. When asked how
their risk compares to the average woman, 25 women (96%) stated that their risk is higher than
the average. 1 woman (4%) recorded her risk as a “little lower” than the average woman’s.

Cancer worry and anxiety
Cancer-related worry was measured using the Lerman cancer worry scale adapted for
ovarian cancer. Our mean score was 5.04 out of 12 with a range of 3-11. We also measured
women’s anxiety using the STAI and found that the mean trait anxiety score was 35.6 with a
range of 21-57. The previously published trait anxiety mean for women ages 19-39 is 36.5, for
ages 40-49 is 35.03 and for ages 50-69 is 31.79 [33].

Intent for RRSO
All 26 women (100% CI: 86.8-100) reported an intention to have an RRSO during their
lifetime (Figure 1). The majority of women (21, 81%) wanted to have surgery prior to age 50, 5
reported “after age 50”, and no one indicated “after menopause”. The most commonly reported
timing for both BRCA1 and BRCA2 mutation carriers was age 41-45. All but 3 women with a
BRCA1 mutation plan to have an RRSO before age 45, and all but 2 BRCA2 carriers desire the
surgery before age 50.
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Gynecologic History
Premenopausal
Post-menopausal
Parity
Parous
Mean age at parity (Range)
History of hysterectomy
History of tubal ligation
Oral contraceptive use
Average time between BRCA results and 1st
gynecologic screening visit (Range)a
Followed for less than 1 year in screening
clinic
Mean length of follow up in ovarian screening
clinic (Range)
Abnormal CA-125 result(s)
Abnormal TVUS result(s)
Breast History
Followed in breast screening clinic
Mean follow-up in breast screening clinic
Any Mastectomy
Bilateral risk-reducing mastectomy
Bilateral mastectomy for treatment
Unilateral risk-reducing mastectomyb
Unilateral mastectomy for treatment
Tamoxifen use
Mean length of use

Number of
Participants
15/26
11/26

Percentage (%)
58
42

21/26
22.6 (15-33) years

81

4/26
7/26
13/26

15
27
50

4.0 (1-13) months

17/26

65

12.9 (0-82) months

1/26
0/26

4
0

20/26
29.1 months

77

15/26
5/26
2/26
6/26
8/26

58
19
8
23
31

3/26
9.3 months

12

Table 2: Gynecologic and breast history of survey participants
RRSO = Risk-reducing salpingo-oophorectomy.
a
Only calculated for women who received BRCA genetic testing through MD Anderson
b
All occurred simultaneously with mastectomy for cancer treatment
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14

BRCA1
BRCA2

12

Number of Participants

10

7
8

6

4

3
6
5
2

2
2
1

0

Age 35-40

Age 41-45

Age 46-50

After age 50

After
Menopause

Never

Figure 1: BRCA mutation carriers’ intended timing for RRSO
Women were asked to indicate if and when they plan to have an RRSO in their lifetime. The
answers for each category were further divided by BRCA1 and BRCA2 mutation status.
RRSO = Risk-reducing salpingo-oophorectomy.
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Motivations for RRSO
Figure 2 summarizes the reported factors motivating women to have an RRSO. Of the
17 provided answers, including one free response option “other”, 16 were selected by at least
one woman as influencing her decision making. On average each woman indicated 6.7 unique
motivations (range: 1-9) and the most commonly selected answer (n=24) was “I want to live
longer for my family”. Women were also asked to rank their top 5 selected motivations and
from this 6 different factors were identified as the 1st or “most important” motivation for RRSO
by 1 or more women. The most common 1st motivation was “I want to live longer for my
family” (n=10), followed by “This surgery will reduce my risk for ovarian cancer” (n=5). A
weighted ranking scoring algorithm was then used to identify the overall most important
motivations for our population (Table 3). This analysis determined that the 5 most important
motivations included: 1) I want to live longer for my family, 2) This surgery will reduce my risk
for ovarian cancer, 3) I have a high risk for ovarian cancer, 4) I have a personal history of
cancer, 5) I have a family history of ovarian cancer.

Barriers to RRSO
Information regarding women’s reported barriers to RRSO is presented in Figure 3.
Women were provided with 24 possible answers, including one free response option “other”,
and of those, 20 were selected. The average number of barriers reported per woman was 2.9,
with a range of 0-8. The most commonly selected barrier was “I am worried about the
symptoms of menopause (e.g. hot flashes or night sweats) (n=11). When participants were
asked to rank their top 5 reasons to delay or avoid RRSO, 11 unique barriers were recorded,
with the most common 1st reason being “I am currently completing treatment for another type of
cancer” (n=6). Because RRSO is almost always contraindicated during cancer treatment, we
13

corrected this bias by removing all women who were currently undergoing cancer treatment
from the weighted scoring analysis for barriers to surgery. After reanalyzing the data and
applying the scoring algorithm the 5 most important barriers included: 1) I am worried about
menopause symptoms (e.g. hot flashes and night sweats), 2) I do not have time for the surgery
and/or recovery, 3) I am worried about the menopause-associated sexual problems (e.g. loss of
sexual drive and vaginal dryness), 4) I am afraid of the surgery and/or recovery, 5) I plan to
have the surgery when I am older (Table 3).

14

I want to live longer for my family
I have a high risk for ovarian cancer
This surgery will reduce my risk for ovarian cancer
My doctor told me I should have this surgery
I am finished having children
I will feel a sense of relief after surgery
I have a personal history of cancer
Ovarian cancer screening is not effective
I have a family history of ovarian cancer
This surgery will reduce my risk for breast cancer
I have already gone through menopause
The surgery and/or recovery are easy
Screening has been stressful and/or time consuming
Other
This surgery will help with other gynecologic
problems
I have heard about celebrities that have had this
surgery
A friend or family member told me I should have this
surgery
0

1st

2nd

3rd

4th

2

4

5th

6

8 10 12 14 16 18 20 22 24
Number of Participants

Not in top 5

Figure 2: Reported motivations for RRSO
Women were asked to select any factors that were motivating them to have an RRSO.
Following this, women were given the opportunity to rank their selections from 1 to 5 with 1
being the most important to their decision making and 5 being the least important.
RRSO = Risk-reducing salpingo-oophorectomy.
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Weighted Score
Motivations
I want to live longer for my family

78

This surgery will reduce my risk for ovarian cancer

78

I have a high risk for ovarian cancer

52

I have a personal history of cancer

39

I have a family history of ovarian cancer

33

Barriers
I am worried about menopause symptoms
(e.g. hot flashes and night sweats)

37

I am currently completing treatment for another type of
cancer

33

I do not have time for the surgery and/or recovery

17

I am worried about menopause-associated sexual problems
(e.g. loss of sex drive and vaginal dryness)

17

I am afraid of the surgery and/or the recovery

16

Barriers
(corrected for current cancer treatment)
I am worried about menopause symptoms
(e.g. hot flashes and night sweats)

32

I do not have time for the surgery and/or recovery

13

I am worried about menopause-associated sexual problems
(e.g. loss of sex drive and vaginal dryness)

13

I am afraid of the surgery and/or the recovery

12

I plan to have the surgery when I am older

15

Table 3: Weighted scores for the top 5 motivations and barriers to RRSO
Women were asked to separately rank the 5 most important motivations for and barriers to
RRSO from 1-5. 1 was considered the most important motivation or barrier and 5 was the least
important. A weighted scoring algorithm was used for comparisons. A rank of 1 was given 5
points, 2 was 4 points, 3 was 3 points, 4 was 2 points and 5 was 1 point. The total scores for the
top 5 answers for each category are summarized here. Analysis of the barriers was corrected for
women currently undergoing cancer treatment because RRSO is contraindicated.
RRSO = Risk-reducing salpingo-oophorectomy.
16

I am worried about the symptoms of menopause
I am currently completing treatment for another type of
cancer
I am worried about menopause-associated sexual
problems
I do not have time for the surgery and/or recovery
I am worried about menopause-associated risk for
osteoporosis
I plan to have the surgery when I am older
Ovarian cancer screening is available
I am worried about menopause-associated risk for heart
disease
I am afraid of the surgery and/or the recovery
I do not have a family history of ovarian cancer
I have not reached the age for surgery recommended by
my doctor
I want to have children, or more children
Other
Having this surgery will not eliminate my risk for
ovarian cancer
I will feel like less of a women if I have my ovaries
removed
I can't pinpoint the reason, but I just don't want to have
the surgery right now
I feel like my life will be worse after the surgery
My insurance will not cover this surgery
I would still be at risk for other cancers after this surgery
I just received my genetic test results
I feel reassured when my ovarian cancer screening is
normal
Other women have had bad outcomes from this surgery
My significant other does not want me to have my
ovaries removed
I have a low risk for ovarian cancer

0

1st

2nd

3rd

4th

2

5th

4
6
8
Number of Participants

10

12

Not in top 5

Figure 3: Reported barriers to RRSO
Women were asked to select any factors that would delay or prevent them from having an
RRSO. Following this women were asked to rank their selections from 1 to 5 with 1 being the
most important factor to their decision making and 5 being the least important.
RRSO = Risk-reducing salpingo-oophorectomy.
17

DISCUSSION
Currently, the NCCN recommends RRSO as the primary ovarian cancer management
option for women with HBOC over the age of 35. Despite its ability to reduce ovarian cancer
risk and potentially breast cancer risk, not all women with a BRCA mutation elect RRSO. A
number of past research studies, both qualitative and quantitative, have identified a variety of
factors that may influence a women’s decision to undergo or avoid surgery; however, to our
knowledge no study to date has asked women to rank the relative importance of these factors.
For this reason, we prospectively investigated the surgical intentions of women with BRCA
mutations currently undergoing ovarian cancer screening, as well as their most important
motivations and barriers to RRSO. The strength of our study design is that we captured women
within their decision making process at the ages most relevant to RRSO.
Overall 74% of women completed our survey indicating that the results likely represent
the population of women attending our screening clinic and may be generalizable to women in
other screening clinics. Based on the responses, all 26 women (100% CI: 86.8-100) intended to
have an RRSO during their lifetime. While few previous studies have measured BRCA
mutation carriers’ surgical intentions, rather than uptake, a study by Tiller et al. in Australia
found that 68% of women planned to have an RRSO after a positive genetic testing result [14].
Our estimate could be higher due to the fact that women attending a screening clinic may be
more inclined towards RRSO than the average woman with HBOC. Additionally, our results
suggest that all of the women surveyed were using screening as a temporary option until their
future surgery, rather than a replacement for RRSO. Of note, 5 women (19%) listed the
availability of screening as a reason to delay or avoid RRSO. This result is concerning given
that screening is not an effective management option for ovarian cancer, and we encourage
healthcare providers to continually emphasize this to their patients. A limited number of studies
18

have investigated the process by which women with HBOC transition from intending to have
surgery to actually undergoing the procedure; however, evidence suggests that women with
BRCA mutations prefer a shared decision making process with their health care provider [14,
34]. An interesting follow-up to this study would be to re-contact women who reported an intent
for RRSO to measure the actual rate of surgical uptake and elucidate how this decision was
finalized.
Regarding the specific timing for RRSO, most women with a BRCA1 mutation reported
a plan to have an RRSO prior to age 45, while many of those with a BRCA2 mutation reported
timing up to age 50. Both of these timing preferences are within 5 years of the current NCCN
management guidelines that recommend RRSO between ages 35-40 for women with a BRCA1
mutation and between ages 40-45 for those with a BRCA2 mutation. Notably, the majority of
women with a BRCA1 mutation who indicated age 40-45 were already over the age of 40 when
they received their genetic testing results, which likely explains their timing. As well, because a
large portion of women were undergoing cancer treatment, surgery may not have been possible
within the recommended timeline. 5 women in our population did report a desire to have an
RRSO after age 50; however, all of these women were ≥50-years-old (range: 50-66) at the time
of survey, and 4 of the 5 received their genetic testing results after age 50. Again, the RRSO
timing for these women is more likely explained by the age at which they received their
mutation results, rather than a deviation from current guidelines. Importantly, we also found that
none of the women indicated a desire to wait until after menopause, which is consistent with the
NCCN guidelines for reducing breast cancer risk. Overall these results emphasize that women
within a screening clinic intend to have an RRSO at an age that is consistent with, or close to
those recommended by the NCCN.
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We next investigated the factors motivating women to pursue an RRSO. 16 of the 17
possible motivations were selected by our participants, indicating that a variety of factors
encourage women to elect surgery. Further, the average number of motivations selected by each
woman was 6.9, highlighting that even for an individual there are multiple reasons she may opt
for an RRSO. Of note, more than half of the selected factors were chosen by >40% of women
and the 3 most common answers were chosen by ≥88%. This indicates that most motivations
were shared across the women in this study, and suggests that within the context of a high-risk
screening program women identify multiple similar reasons to elect RRSO. Additional studies
are needed to determine if this finding holds true for BRCA mutation carriers in other high-risk
screening programs and those who do not elect screening.
Based on the weighted ranking analysis the most important motivations for women in
our population included a desire to reduce one’s ovarian cancer risk, and a desire to live longer
for family members. Previous literature has demonstrated an association between cancer risk
perception and uptake of RRSO [14] and one study has even cited “wanting to reduce ovarian
cancer risk” as the most important influence on RRSO decision making [15]. This motivation
agrees with women’s answers regarding risk perceptions, as the vast majority of them reported a
higher than average perceived risk for ovarian cancer. We also measured cancer worry using the
Lerman cancer worry scale and found that the mean score of 5.03 out of 12 (range 3-11) was
similar to previously reported values for women with BRCA mutations [21, 35] and
corresponds to a moderate level of worry [35]. This supports the influence of ovarian cancer
risk and the desire for risk reduction through RRSO in women with HBOC.
Besides wanting to reduce their ovarian cancer risk women were also very motivated by
a will to live longer for family members. While the weighted score for this motivation was the
same as risk reduction, wanting to live longer for family members was the most commonly
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selected motivation and the most commonly reported 1st motivation among women. Few studies
have previously investigated how the idea of family responsibilities or obligations influence
RRSO; however, Hallowell, 1998 noted that all of her 41 study participants felt compelled to
understand and reduce their cancer risks so that they could better care for their family. This
finding is important because most conversations about RRSO are centered on the patient’s
individual outcomes (e.g. personal cancer risk reduction), while our data suggest that the
discussion should additionally focus on how having surgery will benefit other family members
and may increase a woman’s time with them.
Personal history of any cancer and family history of ovarian cancer were the 4th and 5th
most important motivations for RRSO. In our population all of the women who selected
personal history of cancer had a history of breast cancer, which has been cited by multiple
studies as a significant influence on RRSO [12, 13]. Moreover, given that this group comprised
57% of our study population it is not surprising that a history of cancer was among the most
important factors. Past literature has been more conflicted over the influence of family history
of ovarian cancer on RRSO [8, 17, 36]; however, our study supports a strong influence. Of note,
we did not record the number of family members with ovarian cancer or their degree of
relationship, and thus could not determine if either of these variables impact women’s
responses. Regardless, we encourage healthcare providers to always consider a woman’s
personal and family history of cancer when discussing RRSO.
In addition to motivations, we also investigated the barriers that women perceive to
RRSO. Of the 24 provided reasons one might delay or avoid surgery 20 were selected,
emphasizing that much like the motivations, there are a range of barriers influencing women in
our population. However, unlike for the motivations, the average number of barriers per woman
was 2.9. Despite the lower average number per women, 11 separate barriers were chosen as
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women’s 1st or “most important”. Moreover, 9 of the 26 women (35%) only reported 1 barrier
and of those 9, 6 (66%) regarded it as their most important reason to delay or avoid RRSO. It
appears that the majority of women have a few, but very important barriers that may not be
universal for other BRCA mutation carriers. This novel finding suggests that when counseling
about RRSO it is imperative to elicit the barrier(s) that are influencing each specific woman, as
responses are likely to vary between individuals.
For the barriers that were shared between women we performed a weighted ranking
analysis after correcting for women currently completing breast cancer treatment. This analysis
revealed that the fear of menopausal symptoms (e.g. hot flashes and night sweats) was the most
important barrier to women in our study. Importantly, when we looked specifically at the 15
premenopausal women, 10 of them (66%) had selected this barrier. 1 postmenopausal woman
also chose this barrier. Moreover, worry about menopause-related sexual problems (e.g. loss of
libido and vaginal dryness) was tied for the second most important barrier, indicating that
women were concerned about multiple issues related to menopause. These are notable findings
given that past literature has conflicted regarding the influence of surgically induced menopause
on RRSO decision making [10, 19, 20, 24, 29, 37]. Our study clearly demonstrates that among
premenopausal women, the onset of menopause is one of, if not the most important barrier to
RRSO and healthcare providers should incorporate this into their discussion, if they do not
already. This is especially relevant given the recent evidence that prophylactic salpingectomy
with delayed oophorectomy (PSDO) may provide an attractive alternative for BRCA carriers
who are interested in avoiding early menopause [38, 39]. Future clinical trials are needed to
assess the impact of PSDO on ovarian cancer risk and quality of life in BRCA mutation carriers.
Other important barriers to RRSO included not having time for the surgery, fear of the
surgical risks, and planning to have the surgery at an older age. Brain et al., 2004 previously
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reported that taking time off work for an RRSO and the subsequent recovery was one of the
greatest perceived obstacles to women [10]. Given that the majority of women who completed
our survey are employed, this concern could be particularly relevant to them. Regarding the
desire to have surgery at an older age, all of the women who selected this barrier were either on
the early side of the recommended age spectrum, or were younger than the NCCN
recommended ages. More specifically, 2 BRCA1 carriers (ages 35 and 36) were just within the
recommended timing for RRSO (age 35-40) while the 3 BRCA2 carriers (ages 36, 37, and 37)
were younger than the prescribed age for RRSO with a BRCA2 mutation (age 40-45). This
finding could highlight that some women may prefer to delay surgery till the latest
recommended age. As well, some healthcare providers might support, or even encourage this
preference given that the risk for ovarian cancer is 2-3% by age 40 in BRCA1 carriers and 2-3%
by age 50 in BRCA2 carriers [40, 41]. For this reason, clinicians should inquire about a
woman’s specific timing preferences even within the recommended age ranges.
One of the most consistently published barriers to RRSO is parity. In our population we
did not find this to be one of the top 5 barriers; however, the majority of women in our study
were parous and nearly half were postmenopausal. Many of the previous studies that evaluated
the influence of parity did so in populations that included women under the age of 35, and may
have been less likely to have completed childbearing. Our data suggests that for women who are
within the NCCN recommended ages for RRSO the desire for children (or more children) may
not be as common. We did find that when a desire for children was reported (n=3) it was always
considered the most important barrier to RRSO, which is consistent with past studies [8, 9, 20].
From this we infer that while fewer women age 35 or older may want to have children, it is
likely to be the most important barrier to RRSO if they do.
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There are several limitations to our study. First we had a lower number of participants so
the generalizations that can be drawn from our data may be limited. Moreover, all participants
were recruited from the same MD Anderson screening clinic and the majority of respondents
were white and well-educated. With this in mind, our results may not be representative of
minority or lesser-educated women with BRCA mutations. As well, our population could be
more motivated to address their ovarian cancer risk than others given their willingness to come
for ovarian cancer screening every 6 months.
In conclusion, through this prospective survey of surgical decision making in women
with BRCA mutations we found that 100% intend to pursue an RRSO. The majority of women
were similarly motivated by their desire to reduce their ovarian cancer risk, as well as live
longer for their family. We determined that most women have a few unique barriers to surgery
and this is important to keep in mind when counseling about RRSO. The most important barrier
to our population was the fear of menopause, especially in premenopausal women. Future
studies are needed to confirm the findings of this study in more diverse HBOC populations,
particularly the influence of menopause on decision making. However, our results may be
helpful to healthcare members providing surgical counseling in the context of a high-risk
ovarian cancer screening clinic.
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